Singapore markets closed

Avacta Group Plc (RTQ1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.5450-0.0250 (-4.39%)
At close: 08:02AM CET
Full screen
Previous close0.5700
Open0.5450
Bid0.5550 x N/A
Ask0.6100 x N/A
Day's range0.5450 - 0.5450
52-week range0.5450 - 1.8200
Volume903
Avg. volume45
Market cap198.905M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

    5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide dru

  • GlobeNewswire

    Appointment of Chief Business Officer

    19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical progress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Simon has over 26 years’ commercial experience in the biopharm

  • GlobeNewswire

    ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

    This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 13 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) ALS-6000-101 Phase 1a Three-Weekly Dose Escalatio